Ehrlichia Chaffeensis IgG Titer

A fever, a pounding headache, and a rough week after time outdoors in tick country can be many things. One of them is ehrlichiosis. It's a bacterial infection carried by ticks, and it can turn serious when treatment is delayed.

This established antibody test measures IgG that reacts with Ehrlichia chaffeensis, the bacterium that causes human monocytic ehrlichiosis. IgG is a class of immune protein that can persist after an infection has cleared. The test uses serum from a blood draw and reports an antibody titer by indirect immunofluorescence, or IFA. Its strongest diagnostic use is comparing samples from the beginning of an illness and recovery.

What the Titer Means

A titer is the highest dilution of your serum at which the lab can still detect a specific antibody reaction. The lab applies diluted serum to slides containing bacterial material, adds a fluorescent reagent, and examines the slides under a microscope. A result of 1:256 means the reaction remained detectable after a 256-fold dilution. A larger second number generally indicates stronger antibody reactivity, but it doesn't measure how many bacteria are in your body.

The usual dilution steps double. A fourfold rise spans two steps and, together with a compatible illness, provides confirmatory evidence of recent ehrlichiosis. A single result cannot establish when exposure occurred, and cross-reactions can prevent the antibody test from identifying the exact species.

Human Monocytic Ehrlichiosis

The illness often starts with fever, headache, muscle aches, and fatigue. A systematic review of published cases reported fever in 95%. Low platelets appeared in about four in five cases, raised liver enzymes in about two in three, and low white blood cells in more than half. These estimates came largely from case reports and case series, which can overrepresent severe illness.

Severe infection can cause lung or kidney failure, inflammation of the brain and its lining, and dangerous bleeding or clotting problems. An excessive immune reaction that damages blood cells and organs has also been reported.

People with weakened immunity have a greater risk of severe disease. A case series of 21 people with HIV documented life-threatening illness, particularly with E. chaffeensis infection. Transplant recipients are also vulnerable. Rare transmission through donated organs has occurred, including a documented infection passed through a living donor's kidney.

Why an Early Negative Doesn't Clear You

Antibodies often remain undetectable during the first week of illness. In a small study of nine people with culture-proven E. chaffeensis infection, serum IgG testing detected only three at their initial presentation. PCR testing of whole blood detected bacterial DNA in all nine, while blood-smear microscopy detected bacterial clusters in only two. These findings show the limitations of early antibody testing; they don't establish that PCR detects every infection.

PCR looks for the bacterium's DNA and is most useful early in the illness. Its sensitivity falls after effective antibiotics begin. A negative PCR result also cannot exclude ehrlichiosis.

Follow-up antibody testing is often incomplete. One North Carolina analysis found that only about 15% of people tested for ehrlichiosis or spotted fever rickettsiosis had a recovery sample tested. Another study of testing patterns in the Southeast found ehrlichiosis was tested for less often than spotted fever rickettsiosis, despite overlapping symptoms. A separate analysis found that fewer than one in five people eligible for early PCR testing completed follow-up antibody testing.

Why Antibodies Can Remain After Recovery

Ehrlichia antibodies can persist for months and sometimes years after an infection has resolved. A positive result can therefore reflect past exposure, a current infection, or a cross-reaction. The number alone doesn't distinguish these possibilities.

Some detailed persistence studies concern anaplasmosis, which is caused by a related but different bacterium. One study measured combined antibody responses to that organism and found that half of the small group tested around a year after illness still had detectable antibodies. Another documented persistence in some people for 42 months. These are supporting observations about a different antibody measurement, not a timetable for your E. chaffeensis IgG result.

In a study of 488 North Carolina adults, a minority had serum IgG reactive to Ehrlichia. Those antibodies weren't associated with chronic musculoskeletal symptoms or symptomatic knee osteoarthritis. The study doesn't explain every persistent symptom, but it doesn't support using an isolated positive titer as the explanation for chronic joint pain.

A separate North Carolina survey found Ehrlichia IgG in about one in five Latino food-processing workers and family members. That study measured antibodies in plasma, a different blood fraction from the serum used here. Antibody positivity clustered within households, but it wasn't significantly associated with indoor versus outdoor work. The findings describe exposure in that community and don't establish how a particular activity changes your serum titer.

When Results Can Be Misleading

• Cross-reactions with Anaplasma: these bacteria share some features recognized by antibodies. In a historical referral study, a substantial share of the people whose serum reacted to Anaplasma antigen also reacted to E. chaffeensis antigen. This was a finding among antibody-reactive samples, not a universal cross-reaction rate among people with confirmed anaplasmosis.
• Other Ehrlichia species: E. ewingii can cause a similar illness and produce antibodies that react with E. chaffeensis antigen. Routine antibody testing cannot reliably separate Ehrlichia species.
• Autoimmune disease: false-positive Ehrlichia antibodies have been reported during active lupus. The evidence includes a case report; it doesn't establish how often this happens.
• A weak antibody response: some people with substantial immune suppression develop delayed, weak, or absent antibodies despite infection.
• Very early treatment: limited clinical evidence suggests that early tetracycline-class treatment can sometimes reduce the antibody response. An absent rise therefore needs to be interpreted with the illness history and other testing.
• Differences between laboratories or runs: IFA involves visual interpretation, and antigen preparations and reading techniques can differ. A one-step change may reflect assay variation. Comparisons are most reliable when paired samples are tested together by the same laboratory.
• Sample quality: marked blood-cell breakdown, excess fat in the sample, or contamination can interfere with testing or make a specimen unsuitable.

Testing Ehrlichia and Anaplasma antibodies side by side can help interpret overlapping reactions. A larger titer to one organism does not reliably settle the species or prove two infections are present. Species-specific PCR can provide more direct identification when bacterial DNA is detectable.